Pricing

SPHERA FUNDS MANAGEMENT LTD.

0 followers ·
TEL AVIV L3
13F Summary

Subscription Required

Equal-WT
WhaleScore 2.0 ?

85

S&P 500
WhaleScore ?

Subscription Required

Equal-WT
WhaleScore 1.0 ?

Sphera Funds Management Ltd. is based out of Tel Aviv. Their last reported 13F filing for Q1 2024 included $711,744,424 in managed 13F securities and a top 10 holdings concentration of 33.84%. Sphera Funds Management Ltd.'s largest holding is Teva Pharmaceutical Industries Ltd, ADR with shares held of 3,132,700. Whalewisdom has at least 47 13F filings, 57 13G filings, and 2 Form 4 filings

2024-03-31

Top Buys (13F)

Name % Change
TEVA Teva Pharmaceutical (CALL) 4.05%
CATX Perspective Therapeu 2.08%
CYBN Cybin Inc 1.49%
NICE Nice Ltd ADR 0.97%
OTLK Outlook Therapeutics 0.96%

2024-03-31

Top Sells (13F)

2024-03-31

13F Holdings Summary

Name $ Change
TEVA Teva Pharmaceutical (CALL) 6.21%
XBI SPDR Biotech ETF(PUT) 5.07%
TEVA Teva Pharmaceutical 3.75%
SNY Sanofi SA 3.41%
NICE Nice Ltd ADR 3.14%
Investment discretion with regard to a portion of the securities reported herein exercised by Sphera Portfolio Management Ltd, which is wholly owned by Sphera Funds Management Ltd. Per guidance received from the Division of Investment Management, since Sphera Portfolio Management Ltd does not meet the Section 13(f) securities threshold, its holdings are aggregated with those reported for Sphera Funds Management Ltd. Investment discretion with regard to a portion of the securities reported herein is exercised by Sphera Global Healthcare Management L.P. (the "Management Company"). The Management Company is managed, controlled, and operated by its general partner, Sphera Global Healthcare GP Ltd. (the "General Partner"), the shares of which are owned 90% by Sphera Funds Management Ltd. ("SFML"). SFML is entitled to appoint the members of the board of directors of the General Partner (the "Board of Directors"), and therefore may be deemed to control the General Partner and Management Company. This Form 13F shall not be construed as an admission by SFML, Sphera Portfolio Management, the General Partner, or the Management Company that it is the beneficial owner of any of the securities covered by this Form 13F, and each of SFML, Sphera Portfolio Management, the General Partner, and the Management Company disclaim beneficial ownership of any such securities. Per informal guidance received from the Division of Investment Management, section 13(f) securities that are dual listed on a U.S. stock exchange and the Tel Aviv Stock Exchange were included in this Form 13F only if they were purchased in the U.S..

2024-03-31

13F Activity

Market Value $0.71b, Prior: $0.62b
Inflows (Outflows) as % of Total MV (-1.946)%
New Purchases 27 stocks
Added To 26 stocks
Sold out of 22 stocks
Reduced holdings in 33 stocks
Top 10 Holdings % 33.84%
Turnover %[1] 38.89%
Turnover Alt %[2] 23.03%
Time Held Top 20 4.25 quarters
Time Held Top 10 2.2 quarters
Time Held All 4.23 quarters

[1]: Turnover is calculated by taking the # of new holdings (initial purchases) + the # of positions sold out of (not just reduced) divided by the total # of holdings for the quarter.

[2]: Alt Turnover is calculated by taking either the total MV of new purchases or the MV of securities sold, whichever is less, divided by the total MV of the fund.

2024-03-31

13F Sector Allocation Over Time

2024-03-31

Analysis

Top 20 equal-weighted holdings. Performance numbers calculated through 2024-03-31

Portfolio Performance